BioLargo, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Dennis Calvert
- Full Time Employees
- 45
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- 14921 Chestnut Street Westminster CA United States of America 92683
- IPO Date
- Mar 22, 2007
- CIK
- 0000880242
- Website
- biolargo.com
- Similar Companies
- Business
- BioLargo, Inc. innovates, engineers, and markets a range of proprietary technologies. The company’s solutions address critical environmental issues, including per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor and volatile organic compound (VOC) management, air quality improvement, and infection control. With a foundation of extensive research and development, it holds numerous issued patents, cultivates a robust product pipeline, and offers comprehensive environmental engineering services. Among its offerings are the Aqueous Electrostatic Concentrator (AEC) system, designed for efficient PFAS removal from water, and the Advanced Oxidation System (AOS), which rapidly eliminates pathogens and complex contaminants. Its CupriDyne Clean industrial products are formulated to neutralize challenging odors and VOCs across various industrial environments. The company also develops advanced wound care and surgical irrigation products through its Clyra Medical Technologies subsidiary, including the ViaCLYR™ Wound Irrigation Solution. Additionally, BioLargo is advancing its Cellinity Liquid Sodium Battery technology for long-duration energy storage. BioLargo, Inc. was established in 1991 and maintains its operations in Westminster, California.
Company News
BioLargo, Inc. (BLGO) Q2 2026 Earnings Call Transcript
BioLargo Canada and Tu Nipi Form Indigenous-Led Partnership to Treat Oil Sands Process Water and More
BioLargo Townhall and Q2 2026 Earnings Results Webcast and Conference Call on Thursday, September 10th, 2026 - 4:00 PM Eastern Time
BioLargo's Subsidiary Clyra Medical Adds Third Distribution Channel Accelerating Commercial Rollout of ViaClyr Wound Irrigation Solution
BioLargo, Inc. to Present at the Inaugural Nasdaq / LD Micro Summit on September 9, 2026
Critical Review: BioLargo (NASDAQ:BLGO) and Akzo Nobel (OTCMKTS:AKZOD)
BioLargo to Participate in Gabelli Funds' 4th Annual PFAS Symposium in New York
Gabelli To Host 4th Annual PFAS Symposium
BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%
BioLargo's Lake Stockholm AEC Installation passes six months of PFAS remediation Topping Two Million Gallons
BioLargo Joins New Jersey Institute of Technology-Led PFAS Consortium; President Tonya Chandler Appointed to Board of Directors
BioLargo Equipment Solutions & Technologies' "PFAS Lady" to Teach PFAS 101 at 41st Annual Tri-State Seminar
BioLargo PFAS Treatment Technology Featured in The Disruptive Quarterly
BioLargo Relaunching CupriDyne(R)-Based Consumer Products - Back by Popular Demand and Generated More than $125 Million in Pet-Care Sales
BioLargo Engineering Unit Awarded $1.4 Million in U.S. Air Force Environmental Contract Renewals
BioLargo, Inc. (BLGO) Shareholder/Analyst Call Transcript
BioLargo Subsidiary Clyra Medical Signs Exclusive Distribution Agreement with Al- Hikma FZCO for ViaCLYR(TM) Across the Middle East, North Africa, and Adjacent Markets
BioLargo Signs Memorandum of Understanding with Aquatech to Accelerate Commercialization of PFAS Treatment Technology
BioLargo to Participate in a Town Hall Meeting Hosted by the BioLargo Shareholder Community on Discord on May 5, 2026
BioLargo (NASDAQ:BLGO) versus Global Partner Acquisition Corp II (NASDAQ:GPAC) Critical Survey